{
    "clinical_study": {
        "@rank": "131255", 
        "acronym": "OITROLC", 
        "arm_group": [
            {
                "arm_group_label": "Arm A", 
                "arm_group_type": "Experimental", 
                "description": "Patients receive concurrent chemoradiotherapy at first\u3002Patients also receive chemotherapy every 3-4 weeks for two cycles after concurrent chemoradiotherapy.\nchemotherapy\uff1a\uff081\uff09 squamous cell carcinoma\uff1aDocetaxel 60mg/m2 d1+Cisplatin 25mg/m2 d1-3.\uff082\uff09non squamous cell carcinoma\uff1a pemetrexed 500mg/m2 d1+Cisplatin 25mg/m2 d1-3."
            }, 
            {
                "arm_group_label": "Arm B", 
                "arm_group_type": "Active Comparator", 
                "description": "Patients receive neoadjuvant chemotherapy every 3-4 weeks for two cycles at first.Patients then receive concurrent chemoradiotherapy after neoadjuvant chemotherapy.\nchemotherapy\uff1a\uff081\uff09 squamous cell carcinoma\uff1aDocetaxel 60mg/m2 d1+Cisplatin 25mg/m2 d1-3.\uff082\uff09non squamous cell carcinoma\uff1a pemetrexed 500mg/m2 d1+Cisplatin 25mg/m2 d1-3."
            }
        ], 
        "brief_summary": {
            "textblock": "This study evaluates the  optimal intervention time of  radiotherapy for oligometastatic\n      stage iv lung cancer."
        }, 
        "brief_title": "The Optimal Intervention Time of Radiotherapy for Oligometastatic Stage IV Non-small Cell Lung Cancer\uff08NSCLC\uff09", 
        "condition": "Oligo-metastatic Stage IV Non-small Cell Lung Cancer\uff08NSCLC\uff09", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma, Non-Small-Cell Lung", 
                "Lung Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  18 to 75 years old , male or female\n\n          -  Pathologically or cytologically proven oligometastatic stage IV NSCLC non-small cell\n             lung cancer\uff08NSCLC\uff09\n\n          -  Primary tumors can be measured\n\n          -  Distant organ metastases number \u2264 5\n\n          -  Karnofsky score >70,Zubrod performance status 0-1\n\n          -  Estimated life expectancy of at least 12 weeks\n\n          -  reproductive age women should ensure that before entering the study period\n             contraception\n\n          -  Hemoglobin\u226510.0g/dL,WBC\u2265 4000 cells/mm\u00b3,Platelet count\u2265100,000 cells/mm\u00b3\n\n          -  Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 2.5 times upper\n             limit of normal,bilirubin normal\n\n          -  Creatinine normal OR creatinine clearance \u2265 60 mL/min\n\n          -  Patients have good compliance to treatment and follow-up of acceptance.\n\n        Exclusion Criteria:\n\n          -  Allergic to pemetrexed, cisplatin, docetaxel and contrast medium\n\n          -  Distant metastases organs > 5\n\n          -  The primary tumor or lymph node already received surgical treatment (except for\n             biopsy)\n\n          -  Patient who received radiotherapy for primary tumor or lymph node\n\n          -  Patient who received the the epidermal growth factor targeted therapy\n\n          -  Patient who received chemotherapy or immunotherapy\n\n          -  Patient who suffered from other malignant tumor\n\n          -  Patient who have taken other drug test within 1 month\n\n          -  Pregnant woman or Lactating Women and Women in productive age who refuse to take\n             contraception in observation period\n\n          -  Subject with a severe allergic history or idiosyncratic\n\n          -  Subject with severe pulmonary and cardiopathic disease history\n\n          -  Refuse or incapable to sign the informed consent form of participating this trial\n\n          -  Drug abuse or alcohol addicted\n\n          -  Subject with a Personality or psychiatric diseases, people with no legal capacity or\n             people with limited capacity for civil conduct"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "420", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 24, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02076477", 
            "org_study_id": "scch201402"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Arm A", 
                    "Arm B"
                ], 
                "description": "Radiation\uff08image-guided radiotherapy\uff09\uff1a\uff081\uff09primary tumors\u22643cm\uff0cHypofractionated radiation therapy\uff0caccumulated dose BED \u226580Gy \uff08central lung cancer\uff09\uff0cBED \u2265100Gy\uff08Peripheral lung cancer\uff09.\uff082\uff09primary tumors\u30093cm\uff0cconventional fractionated radiotherapy\uff0caccumulated dose BED=60-66Gy/30-33f.\uff083\uff09 regional lymph node:conventional fractionated radiotherapy\uff0caccumulated dose BED=60-66Gy/30-33f.\uff084\uff09 Brain metastases\uff1a whole brain radiation therapy\uff0c36Gy/12f,Intracranial metastases\uff0c48Gy/12f.\uff085\uff09 bone metastasis\uff1a36 Gy/12f.", 
                "intervention_name": "concurrent chemoradiotherapy", 
                "intervention_type": "Radiation"
            }, 
            {
                "arm_group_label": [
                    "Arm A", 
                    "Arm B"
                ], 
                "description": "Docetaxel:60mg/m2 d1,Given IV", 
                "intervention_name": "Docetaxel", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Arm A", 
                    "Arm B"
                ], 
                "description": "pemetrexed: 500mg/m2 d1,Given IV", 
                "intervention_name": "pemetrexed", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Arm A", 
                    "Arm B"
                ], 
                "description": "Cisplatin\uff1a25mg/m2 d1-3\uff0cGiven IV", 
                "intervention_name": "Cisplatin", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Docetaxel", 
                "Pemetrexed", 
                "Cisplatin"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "intervention time", 
            "radiotherapy", 
            "oligometastatic", 
            "non-small cell lung cancer"
        ], 
        "lastchanged_date": "February 27, 2014", 
        "location": {
            "contact": {
                "email": "litaoxmf@163.com", 
                "last_name": "TAO LI, MD, PhD", 
                "phone": "86-18908178818"
            }, 
            "facility": {
                "address": {
                    "city": "Chengdu", 
                    "country": "China", 
                    "state": "Sichuan", 
                    "zip": "610041"
                }, 
                "name": "Sichuan Cancer Hospital & Institute"
            }, 
            "investigator": [
                {
                    "last_name": "TAO LI, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "XIAOHU WANG, MD, PhD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "XIAOBO DU, MD, PhD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "BING LU, MD, PhD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "The Prospective,Multicenter,Randomized Controlled Clinical Study of the Optimal Intervention Time of Radiotherapy for Oligometastatic Stage IV Non-small Cell Lung Cancer\uff08NSCLC\uff09", 
        "overall_contact": {
            "email": "litaoxmf@126.com", 
            "last_name": "TAO LI, MD, PhD", 
            "phone": "86-18908178818"
        }, 
        "overall_official": [
            {
                "affiliation": "Sichuan Cancer Hospital & Institute", 
                "last_name": "JIAHUA LV, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "gansu cancer hospital", 
                "last_name": "XIAOHU WANG, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Mianyang central hospital", 
                "last_name": "XIAOBO DU, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Cancer Hospital of Guizhou Province", 
                "last_name": "BING LU, MD.PhD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Ministry of Health", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "January 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Response Evaluation Criteria In Solid Tumors (RECIST)", 
            "measure": "short-term effects\uff08The response rate\uff0cRR\uff09", 
            "safety_issue": "Yes", 
            "time_frame": "3 months after the end of the treatment"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02076477"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Sichuan Cancer Hospital and Research Institute", 
            "investigator_full_name": "LI TAO", 
            "investigator_title": "Section Head", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "PFS\uff08progression-free survival\uff09", 
                "safety_issue": "Yes", 
                "time_frame": "up to 3 years"
            }, 
            {
                "description": "Quality of life (QOL) as measured by the Functional Assessment of Cancer Therapy-Trial Outcome Index (FACT-TOI) and lung cancer subscale (LCS)", 
                "measure": "Quality of life (QOL)", 
                "safety_issue": "Yes", 
                "time_frame": "up to 3 years"
            }, 
            {
                "description": "Grade 3-5 esophagitis and pneumonitis adverse events as assessed by NCI Common Toxicity Criteria for Adverse Effects (CTCAE) v3.0", 
                "measure": "esophagitis and pneumonitis", 
                "safety_issue": "Yes", 
                "time_frame": "up to 3 years"
            }, 
            {
                "description": "Other grade 3-5 adverse events as assessed by NCI CTCAE v3.0", 
                "measure": "Other grade 3-5 adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "up to 3 years"
            }
        ], 
        "source": "Sichuan Cancer Hospital and Research Institute", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "gansu cancer hospital", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Mianyang central hospital", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Cancer Hospital of Guizhou Province", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Sichuan Cancer Hospital and Research Institute", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}